Shots:

• The new data from the post-approval study evaluates the effectiveness & safety of Truxima (CT-P10) in patients with DLBCL in a real-world setting across Europe
• Results: @30mos. post-index- 67% had not experienced disease progression with OS (74%)- three-quarters patients achieved complete or partial response @30mos.- well tolerated with AEs while response rates- survival rates & overall safety profile showed consistency with reference product
• The company also presents real-world data of CT-P10 for NHL & CLL which showed 10% of patients experienced an IRR & were generally well-tolerated- patients achieved a complete response or partial response @6mos. observation period

  | Ref: Business Wire | Image: Celltrion